Phase 2 Brain Cancer Trial, Recruiting NCT06356883 Sponsor: Université de Sherbrooke Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT06356883
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with glioblastoma multiforme (a type of brain tumour), confirmed by a tissue biopsy.
  • Your brain tumour has shown signs of growing again on an MRI scan, after you have already been treated with the standard treatment combining radiotherapy and a chemotherapy drug called Temozolomide (known as the Stupp protocol).
  • You finished your previous radiotherapy and Temozolomide treatment at least 4 weeks ago.
  • You are 18 years of age or older.
  • You are able to carry out most daily activities and care for yourself, as measured by a standard health scoring scale (Karnofsky score between 60–100%).
  • Your blood counts are within acceptable levels — including enough platelets, red blood cells, and white blood cells (confirm with trial site for exact values).
  • Your bone marrow is functioning normally.
  • Your liver is functioning normally, with blood test results for liver enzymes and bilirubin within acceptable ranges.
  • Your kidneys are functioning normally, with kidney-related blood test results within acceptable ranges.
  • Your heart tracing (ECG) is normal.
  • You are willing and able to sign a consent form agreeing to take part.
  • You are either not able to have children, or you have been using a reliable method of contraception for at least 2 months before joining the trial.

Who may not be able to join:

  • You have a serious psychiatric or medical condition that could interfere with receiving treatment or participating in the study.
  • You have an active autoimmune disease (a condition where your immune system attacks your own body).
  • You have had a significant heart condition within the last 5 years, or your heart pumping function is below a certain level on an ultrasound scan (confirm with trial site).
  • You have had another type of cancer in the past 5 years — except for certain fully treated skin cancers or a very early-stage cervical condition.
  • You are pregnant (confirmed by a positive pregnancy blood test) or are currently breastfeeding.
  • You have an active infection that is not under control.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: David Fortin, MD, Estrie University Integrated Health and Social Services Center - University Hospital of Sherbrooke

Phone: 819-346-1110

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Université de Sherbrooke
Registry
ClinicalTrials.gov
Start date
1 August 2025
Est. completion
1 April 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Tumor Response on MRI using the RANO Criteria; Progression-free Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov